To include your compound in the COVID-19 Resource Center, submit it here.

Semuloparin: Phase III data

The double-blind, international Phase III SAVE-ONCO trial in 3,212 cancer patients undergoing chemotherapy

Read the full 138 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE